Who are PF-06882961 (Cohort 3)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Plegisol In Plastic Container, Plegisol In Plastic Container, C. difficile vaccine formulation 1., PF-07220060 + PF-07104091 combination dose escalation, Ly4064809, Other treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-06882961-cohort-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

PF-06882961 (Cohort 3) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-06882961 (Cohort 3) (pf-06882961-cohort-3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Not specified. Area: Oncology.

marketed Not specified Not specified Oncology Live · refreshed every 30 min

Target snapshot

PF-06882961 (Cohort 3) (pf-06882961-cohort-3) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PF-06882961 (Cohort 3) TARGET	pf-06882961-cohort-3	Pfizer	marketed	Not specified	Not specified
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
Plegisol In Plastic Container	Sodium Chloride	Baxter	marketed	Electrolyte solution	Not specified	1965-01-01
C. difficile vaccine formulation 1.	c-difficile-vaccine-formulation-1	Pfizer Inc.	marketed	Vaccine	Not specified
PF-07220060 + PF-07104091 combination dose escalation	pf-07220060-pf-07104091-combination-dose-escalation	Pfizer	marketed	Not specified	Not specified
Ly4064809	ly4064809	Pfizer	marketed	Not specified	Not specified
Other treatment	Other treatment	Novartis Pharmaceuticals	marketed	Not specified	Not specified

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Not specified class)

Pfizer · 17 drugs in this class
BioNTech · 1 drug in this class
Novartis Pharmaceuticals · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Vaxxinity, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-06882961 (Cohort 3) — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-06882961-cohort-3. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab